Poseida Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Poseida Therapeutics (Nasdaq: PSTX), a clinical-stage biopharmaceutical company based in San Diego, pioneered donor-derived, off-the-shelf CAR-T cell therapies for blood cancers, autoimmune diseases and solid tumors. Its non-viral genetic engineering platform produced allogeneic CAR-T candidates, with three programs in Phase 1 trials. In November 2024 Roche agreed to acquire the company for about $1.0 billion in equity value, up to $1.5 billion with milestone payments.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Product launch
Poseida enters a collaboration and licence agreement with Roche to develop off-the-shelf CAR-T therapies for blood cancers.
- Acquisition
Roche agrees on November 26, 2024 to acquire Poseida for $9.00 per share in cash plus up to $4.00 per share in milestone payments; the deal is expected to close in Q1 2025.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.